# OnCo record burosumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/burosumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "burosumab" ;
  schema:name "Burosumab"@en ;
  schema:alternateName "burosumab"@en, "Crysvita"@en, "KRN23"@en, "Crysvita" ;
  schema:description "Crysvita is an antibody for a rare bone-softening condition in which the body leaks phosphate. Some small tumours cause it by making too much of a hormone called FGF23; when the tumour cannot be found or removed, Crysvita blocks the hormone."@en ;
  schema:url <https://onco.cc/drugs/burosumab/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1002/jbmr.4233>, <https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=102f96a0-6e3a-4fc1-b204-34d604683af6> ;
  onco:status "approved" ;
  onco:tag "ema-register", "supportive" ;
  onco:modality "Monoclonal antibody (anti-FGF23)" ;
  onco:approval "EU 2018: X-linked hypophosphataemia; FGF23-related hypophosphataemia in tumour-induced osteomalacia (phosphaturic mesenchymal tumours not curatively resectable or localisable)" ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:trials <https://onco.cc/trials/ux023t-cl201/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/> .